

Xbrane announces two granted patents that strengthens its high yield protein expression platform

Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") (Nasdaq Stockholm: XBRANE) has been granted two new patents by the Swedish patent and Registration Office (PRV). The patents relate to novel methods of using signal peptides to enhance the production yield and thereby lowering the production cost of recombinant proteins expressed in E.coli. The patents are an important additional component to Xbrane's platform technology aimed at enabling development of biosimilar candidates to the lowest production cost possible.

Recombinant proteins are produced via the introduction of a DNA-sequence into a living cell instructing it to produce the protein of interest. Signal peptides typically function to prompt a cell to translocate the recombinant protein, usually through and across the cellular membrane. It has been demonstrated in the patents that certain nucleic acid sequences of the DNA sequences encoding the signal peptides positively impact the production yield, i.e., the amount of the targeted recombinant protein produced at a given scale of fermentation. The patents relate to specific such novel nucleic acid sequences encoding various signal peptides that have been demonstrated to have significant impact on production yield. The mention of the patent grants is available in the latest edition of the Swedish Patent Gazette <https://www.prv.se/en/patents/patent-web-publications/>

An international patent application claiming priority from the patents was filed earlier this year and said international patent application will be followed-up in commercially important jurisdictions.

The patents are jointly owned, to equal shares, by Xbrane Biopharma AB and CloneOpt AB, a Stockholm University spin-out.

The patents are part of many further patents that are likely to be granted to Xbrane in the autumn and form part of 22 patents and patent applications that have been drafted, filed and/or prosecuted by the new IP department established at Xbrane in early 2020.

"We are an innovative company continuously strengthening our platform technology with the focus of having the lowest production cost in the industry of the biosimilars we develop. Going forward we will put more emphasis on building an IP-portfolio around our platform technology to better protect and monetize on our research. The recently granted patents cover new inventions that further strengthens our platform", says Martin Åmark, CEO Xbrane.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally two biosimilar candidates in its pipeline targeting € 7.9bn in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.

For more information, visit www.xbrane.com.

Attachments

[Xbrane announces two granted patents that strengthens its high yield protein expression platform](#)